Brenus -Model STC 1010 -Stimulate Tumor Cell

2 MILLION
patients diagnosed every year

2ND CAUSE
of cancer mortality worldwide

12%
survival rate after 5 years

CHEMOTHERAPIES ALONE IN 1L
with anti-PD1 option only for MSI-H patients (5% of CRC population)

01. To meet the need in targeting treatment resistance
STC-1010 targets MSS and MSI-H population.

02. To meet the need in breaking immunue tolerance
STC-1010 has a robust and validated preclinical data pack showing:

INCREASE IN OVERALL SURVIVAL
in colorectal cold and hot mice model

INCREASE IN CD8+ TUMOR INFILTRATION
in several model

EFFICACY IN ANTI-PD1 RESISTANT
mice model

03. To meet the need for an accessible approach

An OFF-THE-SHELF technology allowing control of both time and cost of the manufacturing process.

Exemple of treatments with a biological rational to combine with STC 1010

Step 1
GM-CSF low dose: Recruits APC at injection point and mature DCs.

Step 2
Checkpoint inhibitors, ADC TLR Promotes T cell priming and activation

Step 3
Chemokyne cytokine TLR : Increase trafficking of T cell

Step 4
Bevacizumab Facilitates infiltration of CD8+ lymphocytes into tumors

Step 5
5FU, Bevacizumab and Cyclophosphamide low dose, radiotherapy. Decrease the activity of immunosuppressive cells (Tregs and MDSCs)

Step 6
Checkpoint inhibitors, ADC, BiSpecific mAb, TLR restores the anticancer immunity